Anna Levy, DO
Hematology & Oncology · New Hyde Park, NYNPI 1275767253
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,625 of the $7,927 with a category attached, or 96.2%. Merck accounts for 77.1% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $6,100 and has fallen 72.5% since, to $1,675 in 2025.
Across 5 payments — averaging $1585.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$6K
- AstraZeneca$2K
- Intera Oncology, Inc$141
Across 35 payments — averaging $10,106 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$210K
- Beigene, Ltd.$73K
- Genentech, Inc.$71K
What the payments were for
- Consulting fees$7,62596%
- Travel & lodging$1502%
- Food & beverage$1412%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 3 | $6,111 |
| AstraZeneca | 1 | $1,675 |
| Intera Oncology, Inc | 1 | $141 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$1,675
- Intera 3000 Implantable Pump$141
How this compares
$7,927 in reported general payments places this provider in the 70th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LytgobiFutibatinib | 15 | $284,356 |
| LonsurfTrifluridine/Tipiracil Hcl | 18 | $216,224 |
| EliquisApixaban | 28 | $23,625 |
| XareltoRivaroxaban | 20 | $16,044 |
| Pantoprazole Sodium | 44 | $421 |
| Famotidine | 33 | $287 |
| Ondansetron Hcl | 39 | $286 |
| Oxycodone Hcl | 27 | $277 |
| Dexamethasone | 19 | $231 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 20 | $196 |
| Mirtazapine | 32 | $174 |
| Prochlorperazine Maleate | 11 | $113 |
| Metoclopramide Hcl | 31 | $63 |
| Potassium Chloride | 16 | $43 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in New Hyde Park
- Richard GrallaNew Hyde Park$159K
- Tarun WasilNew Hyde Park$147K
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Francis ArenaLake Success$1M
- Sanjeev JainEast Patchogue$971K
- Ross LevineNew York$968K
- Perry CookBrooklyn$803K
- Mihir RavalAlbany$767K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.